CSPC pharmaceutical group gets nod for RSV drug clinical trials in China

CSPC Pharmaceutical Group Limited announced that its SYH2066 Tablets, a Class 1 innovative chemical drug, received approval from the National Medical Products Administration of the People's Republic of China to commence clinical trials. The trials are scheduled to begin in September 2025. This oral, small molecule candidate is designed to target respiratory syncytial virus (RSV) and treat associated respiratory infections.

Preclinical studies demonstrated that SYH2066 Tablets possess favorable pharmacokinetic properties, including good oral bioavailability, and significantly reduced RSV viral titers in animal models, exhibiting a high safety profile. The company noted that there are currently no approved small molecule drugs targeting RSV, either domestically or internationally.

CSPC Pharmaceutical Group believes that SYH2066 Tablets have the potential to become an effective therapeutic option for RSV-related diseases, providing significant clinical development value.